Literature DB >> 7681223

Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.

M Levi1, D Roem, A M Kamp, J P de Boer, C E Hack, J W ten Cate.   

Abstract

It has been shown that the most important inhibitor of plasmin is alpha 2-antiplasmin, however, other protease inhibitors are able to inhibit this proteolytic enzyme as well. The contribution of the various protease inhibitors to the inhibition of plasmin in vivo has never been quantitatively assessed. To assess the relative contribution of the different protease inhibitors on the inhibition of plasmin we developed a series of sensitive immunoassays for the detection of complexes between plasmin and the protease inhibitors alpha 2-antiplasmin, alpha 2-macroglobulin, antithrombin III, alpha 1-antitrypsin and C1-inhibitor, utilizing monoclonal antibodies that are specifically directed against complexed protease inhibitors and a monoclonal antibody against plasmin. It was confirmed that alpha 2-antiplasmin is the most important inhibitor of plasmin in vivo, however, complexes of plasmin with alpha 2-macroglobulin, antithrombin III, alpha 1-antitrypsin- and C1-inhibitor were also detected. Particularly during activation of fibrinolysis complexes between plasmin and inhibitors other than alpha 2-antiplasmin were detected. It was observed that during different situations the inhibition profile of plasmin was not constant e.g. in patients with diffuse intravascular coagulation plasma levels of plasmin-alpha 1-antitrypsin and plasmin-C1-inhibitor were increased whereas in plasma from patients who were treated with thrombolytic agents complexes of plasmin with alpha 2-macroglobulin and with antithrombin III were significantly elevated. In conclusion, we confirmed the important role of alpha 2-antiplasmin in the inhibition of plasmin, however, in situations in which fibrinolysis is activated other protease inhibitors also account for the inhibition of plasmin in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681223

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds.

Authors:  B M Schaefer; K Maier; U Eickhoff; M Bechtel; M D Kramer
Journal:  Arch Dermatol Res       Date:  1996-03       Impact factor: 3.017

2.  The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

3.  Contracting scars from fibrin drops.

Authors:  Stephen Robinson; Eric Parigoris; Jonathan Chang; Louise Hecker; Shuichi Takayama
Journal:  Integr Biol (Camb)       Date:  2022-03-21       Impact factor: 3.177

4.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

5.  Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).

Authors:  Friedrich Modde; Putri Andina Agustian; Juliane Wittig; Maximilian Ernst Dämmrich; Vinzent Forstmeier; Udo Vester; Thurid Ahlenstiel; Kerstin Froede; Ulrich Budde; Anne-Margret Wingen; Anke Schwarz; Svjetlana Lovric; Jan Thomas Kielstein; Carsten Bergmann; Nadine Bachmann; Mato Nagel; Hans Heinrich Kreipe; Verena Bröcker; Clemens Luitpold Bockmeyer; Jan Ulrich Becker
Journal:  Virchows Arch       Date:  2013-03-09       Impact factor: 4.064

6.  Aqueous two-phase deposition and fibrinolysis of fibroblast-laden fibrin micro-scaffolds.

Authors:  Stephen Robinson; Jonathan Chang; Eric Parigoris; Louise Hecker; Shuichi Takayama
Journal:  Biofabrication       Date:  2021-04-07       Impact factor: 9.954

7.  Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure.

Authors:  Piet Meijer; Michel Hanss; Ulla Christensen; Bjorn Wiman; Kees Kluft
Journal:  EJIFCC       Date:  2001-07-22

8.  Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study.

Authors:  Maciej Wiktor Polak; Jakub Siudut; Krzysztof Plens; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

Review 9.  A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.

Authors:  Michael E O'Brien; Grace Murray; Debananda Gogoi; Azeez Yusuf; Cormac McCarthy; Mark R Wormald; Michelle Casey; Claudie Gabillard-Lefort; Noel G McElvaney; Emer P Reeves
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

10.  Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report.

Authors:  Koji Sugioka; Aya Kodama; Koji Yoshida; Kiyotaka Okada; Masahiko Fukuda; Yoshikazu Shimomura
Journal:  BMC Ophthalmol       Date:  2012-11-28       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.